Skip to main content
Original article

Which accessible clinical features and laboratory findings might predict methotrexate success in children with juvenile idiopathic arthritis in Bosnia and Herzegovina?

Authors
  • Adisa Čengić orcid logo (Pediatric Clinic, Clinical Centre of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
  • Velma Selmanović (Pediatric Clinic, Clinical Centre of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
  • Sniježana Hasanbegović (Pediatric Clinic, Clinical Centre of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
  • Hamza Izeta (Health Centre of Canton Sarajevo, Sarajevo, Bosnia and Herzegovina)
  • Lamija Zečević (Clinical Immunology, Clinical Centre of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
  • Nejra Džananović (Clinical Immunology, Clinical Centre of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Abstract

Aim: To determine whether demographic data, clinical features, and laboratory variables at disease onset can predict the response to methotrexate in juvenile idiopathic arthritis (JIA) patients.

Methods: A cohort of 143 newly diagnosed JIA patients initially treated with methotrexate was enrolled in this study. Demographic, clinical, and laboratory parameters were analysed using univariate and multivariate logistic regression to identify predictors of response to methotrexate. The variables included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelets, IgA, IgG, the number of active joints and age at disease onset. Treatment response was assessed at six months, with patients classified as responders (those who achieved clinically inactive disease according to the American College of Rheumatology - ACR criteria) or non-responders.

Results: Poor response to methotrexate was associated with the number of active joints (p=0.0001; OR=2.7), baseline levels of CRP (p=0.044; OR=1.138), IgA (p =0.004; OR=2.159), and platelet count (p=0.01; OR=1.05). IgG level (P=0.236) did not correlate with the treatment response.

Conclusion: We identified widely available and clinically acceptable biomarkers that can be utilized as predictive indicators of response to methotrexate in JIA patients.

Keywords: chronic joint inflam-mation, response, treatment

How to Cite:

Čengić, A., Selmanović, V., Hasanbegović, S., Izeta, H., Zečević, L. & Džananović, N., (2025) “Which accessible clinical features and laboratory findings might predict methotrexate success in children with juvenile idiopathic arthritis in Bosnia and Herzegovina?”, Medicinski glasnik 22(1), 48-52. doi: https://doi.org/10.17392/1882-22-01

Downloads:
Download PDF
View PDF

0 Views

0 Downloads

Published on
2025-02-03

Peer Reviewed

License

CC-BY-NC-ND 4.0